Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nephros (NEPH) Asset Writedowns and Impairment (2016 - 2025)

Nephros (NEPH) has 11 years of Asset Writedowns and Impairment data on record, last reported at $15000.0 in Q3 2025.

  • For Q3 2025, Asset Writedowns and Impairment fell 55.88% year-over-year to $15000.0; the TTM value through Sep 2025 reached $104000.0, down 50.71%, while the annual FY2024 figure was $262000.0, 2281.82% up from the prior year.
  • Asset Writedowns and Impairment reached $15000.0 in Q3 2025 per NEPH's latest filing, down from $35000.0 in the prior quarter.
  • Across five years, Asset Writedowns and Impairment topped out at $774000.0 in Q4 2022 and bottomed at -$122000.0 in Q4 2021.
  • Average Asset Writedowns and Impairment over 5 years is $58052.6, with a median of $34000.0 recorded in 2024.
  • The widest YoY moves for Asset Writedowns and Impairment: up 2766.67% in 2021, down 1842.86% in 2021.
  • A 5-year view of Asset Writedowns and Impairment shows it stood at -$122000.0 in 2021, then soared by 734.43% to $774000.0 in 2022, then plummeted by 100.39% to -$3000.0 in 2023, then skyrocketed by 1700.0% to $48000.0 in 2024, then plummeted by 68.75% to $15000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Asset Writedowns and Impairment were $15000.0 in Q3 2025, $35000.0 in Q2 2025, and $6000.0 in Q1 2025.